{"generic":"Candesartan Cilexetil","drugs":["Atacand","Candesartan Cilexetil"],"mono":{"0":{"id":"924785-s-0","title":"Generic Names","mono":"Candesartan Cilexetil"},"1":{"id":"924785-s-1","title":"Dosing and Indications","sub":[{"id":"924785-s-1-4","title":"Adult Dosing","mono":"<ul><li><b>Heart failure, (NYHA class II to IV, ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations:<\/b> initial, 4 mg ORALLY once daily, double dose at approximately 2-wk intervals, as tolerated; target dose 32 mg daily<\/li><li><b>Hypertension:<\/b> initial, 16 mg ORALLY once daily or in 2 divided doses; range 8 to 32 mg ORALLY once daily or in 2 divided doses<\/li><\/ul>"},{"id":"924785-s-1-5","title":"Pediatric Dosing","mono":"<ul><li>not indicated for use in children less than 1 year of age<\/li><li><b>Hypertension:<\/b> (1 to less than 6 yr), initial, 0.2 mg\/kg once daily; dose range 0.05 to 0.4 mg\/kg once daily or in 2 divided doses<\/li><li><b>Hypertension:<\/b> less than 50 kg, (6 to less than 17 yr), initial, 4 to 8 mg ORALLY once daily; dose range 2 to 16 mg\/day once daily or in 2 divided doses<\/li><li><b>Hypertension:<\/b> greater than 50 kg, (6 to less than 17 yr), initial, 8 to 16 mg ORALLY once daily; dose range 4 to 32 mg\/day once daily or in 2 divided doses<\/li><\/ul>"},{"id":"924785-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal insufficiency:<\/b> no initial dose adjustment necessary<\/li><li><b>renal impairment, moderate to severe (CrCl 15 to 60 mL\/min\/1.73 m(2)):<\/b> 8 mg daily may be a sufficient dose<\/li><li><b>hepatic insufficiency, mild:<\/b> no dose adjustment necessary<\/li><li><b>hepatic insufficiency, moderate:<\/b> initiate therapy with 8 mg in adults with hypertension<\/li><li><b>hepatic insufficiency, severe:<\/b> no dose recommendation available<\/li><li><b>geriatric:<\/b> no initial dose adjustment necessary<\/li><\/ul>"},{"id":"924785-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><ul><li>Heart failure, (NYHA class II to IV, ejection fraction 40% or less) to reduce cardiovascular mortality and hospitalizations<\/li><li>Hypertension<\/li><\/ul><b>Non-FDA Labeled Indications<\/b><ul><li>Cerebrovascular accident; Prophylaxis<\/li><li>Diabetic nephropathy<\/li><li>Essential hypertension - Left ventricular hypertrophy<\/li><li>Kidney disease<\/li><li>Migraine; Prophylaxis<\/li><li>Recurrent atrial fibrillation; Prophylaxis<\/li><li>Transplantation<\/li><\/ul>"}]},"2":{"id":"924785-s-2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Drugs that act directly on the renin-angiotensin system can cause injury or death to the developing fetus. Stop therapy as soon as possible when pregnancy is detected.<br\/>"},"3":{"id":"924785-s-3","title":"Contraindications\/Warnings","sub":[{"id":"924785-s-3-9","title":"Contraindications","mono":"<ul><li>hypersensitivity to candesartan<\/li><li>concomitant use with aliskiren in patients with diabetes<\/li><\/ul>"},{"id":"924785-s-3-10","title":"Precautions","mono":"<ul><li>pregnancy; risk of fetal toxicity, especially in the second and third trimesters; discontinue therapy as soon as possible when pregnancy is detected<\/li><li>concomitant use with aliskiren; avoid use in patients with GFR below 60 mL\/min<\/li><li>hepatic impairment, moderate; consider dose reduction<\/li><li>hyperkalemia may occur; monitoring recommended<\/li><li>hypotension may occur, including during major surgery and anesthesia; increased risk in volume- or salt-depleted patients; correct volume and salt depletion before therapy initiation; monitoring recommended; dose reduction may be required<\/li><li>pediatric patients younger than 1 year; drug may affect kidney development; avoid use for hypertension<\/li><li>renal function changes, including acute renal failure, may occur from drugs that inhibit the renin-angiotensin system (RAAS); increased risk in patients whose renal function relies on the RAAS (eg, renal artery stenosis, chronic renal disease, severe heart failure, or volume depletion); monitoring recommended; therapy interruption or discontinuation may be required<\/li><li>report suspected adverse reactions to the US Food and Drug Administration at 1-800-FDA-1088 or www.fda.gov\/medwatch<\/li><\/ul>"},{"id":"924785-s-3-11","title":"Pregnancy Category","mono":"<ul><li>D (FDA)<\/li><li>D (AUS)<\/li><\/ul>"},{"id":"924785-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"924785-s-4","title":"Drug Interactions","sub":{"1":{"id":"924785-s-4-14","title":"Major","mono":"<ul><li>Benazepril (established)<\/li><li>Captopril (established)<\/li><li>Enalapril (established)<\/li><li>Enalaprilat (established)<\/li><li>Fosinopril (established)<\/li><li>Lisinopril (established)<\/li><li>Lithium (theoretical)<\/li><li>Moexipril (established)<\/li><li>Perindopril (established)<\/li><li>Quinapril (established)<\/li><li>Ramipril (established)<\/li><li>Trandolapril (established)<\/li><li>Trimethoprim (theoretical)<\/li><\/ul>"},"2":{"id":"924785-s-4-15","title":"Moderate","mono":"<ul><li>Aceclofenac (probable)<\/li><li>Acemetacin (probable)<\/li><li>Amtolmetin Guacil (probable)<\/li><li>Aspirin (probable)<\/li><li>Bromfenac (probable)<\/li><li>Bufexamac (probable)<\/li><li>Celecoxib (probable)<\/li><li>Choline Salicylate (probable)<\/li><li>Clonixin (probable)<\/li><li>Dexibuprofen (probable)<\/li><li>Dexketoprofen (probable)<\/li><li>Diclofenac (probable)<\/li><li>Diflunisal (probable)<\/li><li>Dipyrone (probable)<\/li><li>Etodolac (probable)<\/li><li>Etofenamate (probable)<\/li><li>Etoricoxib (probable)<\/li><li>Felbinac (probable)<\/li><li>Fenoprofen (probable)<\/li><li>Fepradinol (probable)<\/li><li>Feprazone (probable)<\/li><li>Floctafenine (probable)<\/li><li>Flufenamic Acid (probable)<\/li><li>Flurbiprofen (probable)<\/li><li>Ibuprofen (probable)<\/li><li>Ibuprofen Lysine (probable)<\/li><li>Indomethacin (probable)<\/li><li>Ketoprofen (probable)<\/li><li>Ketorolac (probable)<\/li><li>Lornoxicam (probable)<\/li><li>Loxoprofen (probable)<\/li><li>Lumiracoxib (probable)<\/li><li>Meclofenamate (probable)<\/li><li>Mefenamic Acid (probable)<\/li><li>Meloxicam (probable)<\/li><li>Morniflumate (probable)<\/li><li>Nabumetone (probable)<\/li><li>Naproxen (probable)<\/li><li>Nepafenac (probable)<\/li><li>Niflumic Acid (probable)<\/li><li>Nimesulide (probable)<\/li><li>Oxaprozin (probable)<\/li><li>Oxyphenbutazone (probable)<\/li><li>Parecoxib (probable)<\/li><li>Phenylbutazone (probable)<\/li><li>Piketoprofen (probable)<\/li><li>Piroxicam (probable)<\/li><li>Proglumetacin (probable)<\/li><li>Propionic Acid (probable)<\/li><li>Propyphenazone (probable)<\/li><li>Proquazone (probable)<\/li><li>Rofecoxib (probable)<\/li><li>Salicylic Acid (probable)<\/li><li>Salsalate (probable)<\/li><li>Sodium Salicylate (probable)<\/li><li>Sulindac (probable)<\/li><li>Tenoxicam (probable)<\/li><li>Tiaprofenic Acid (probable)<\/li><li>Tolfenamic Acid (probable)<\/li><li>Tolmetin (probable)<\/li><li>Valdecoxib (probable)<\/li><\/ul>"}}},"5":{"id":"924785-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypotension (18.8%)<\/li><li><b>Musculoskeletal:<\/b>Backache (3%.)<\/li><li><b>Neurologic:<\/b>Dizziness (less than 5%)<\/li><li><b>Respiratory:<\/b>Pharyngitis (2%), Rhinitis (2%), Upper respiratory infection (6%)<\/li><\/ul>"},"6":{"id":"924785-s-6","title":"Drug Name Info","sub":{"0":{"id":"924785-s-6-17","title":"US Trade Names","mono":"Atacand<br\/>"},"2":{"id":"924785-s-6-19","title":"Class","mono":"<ul><li>Angiotensin II Receptor Antagonist<\/li><li>Cardiovascular Agent<\/li><\/ul>"},"3":{"id":"924785-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"924785-s-6-21","title":"Generic Availability","mono":"Yes<br\/>"}}},"7":{"id":"924785-s-7","title":"Mechanism Of Action","mono":"Systemic: Candesartan is a nonpeptide angiotensin II antagonist that selectively blocks the binding of angiotensin II to the AT 1 receptors in tissues such as vascular smooth muscle and the adrenal gland . In the renin-angiotensin system, angiotensin I is converted by angiotensin-converting enzyme (ACE) to form angiotensin II . Angiotensin II stimulates the adrenal cortex to synthesize and secrete aldosterone, which decreases the excretion of sodium and increases the excretion of potassium . Angiotensin II also acts as a vasoconstrictor in vascular smooth muscle . By blocking the binding of angiotensin II to the AT 1 receptors, candesartan causes vasodilation and decreases the effects of aldosterone . The negative feedback regulation of angiotensin II on renin secretion also is inhibited, resulting in a rise in plasma renin concentrations and a consequent rise in angiotensin II plasma concentrations; however, these effects do not counteract the blood pressure-lowering effect that occurs .<br\/>"},"8":{"id":"924785-s-8","title":"Pharmacokinetics","sub":[{"id":"924785-s-8-23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 3 to 4 hr<\/li><li>Bioavailability, Oral: 15%<\/li><li>Effect of food: overall, no effect<\/li><\/ul>"},{"id":"924785-s-8-24","title":"Distribution","mono":"<ul><li>Vd: 0.13 L\/kg<\/li><li>Protein binding: greater than 99%<\/li><\/ul>"},{"id":"924785-s-8-25","title":"Metabolism","mono":"<ul><li>Intestinal wall: greater than 99%<\/li><li>Candesartan: active<\/li><li>Liver: minor<\/li><li>O-deethyl metabolite: inactive<\/li><\/ul>"},{"id":"924785-s-8-26","title":"Excretion","mono":"<ul><li>Bile: some contribution<\/li><li>Fecal: 67% unchanged<\/li><li>Renal: 26% unchanged<\/li><li>Renal clearance: 0.19 mL\/min\/kg<\/li><li>Dialyzable: No<\/li><li>Total body clearance: 0.37 mL\/minute\/kg<\/li><\/ul>"},{"id":"924785-s-8-27","title":"Elimination Half Life","mono":"<ul><li>Adults, 9 hr<\/li><li>Children, 5.7 to 6.7 hr<\/li><\/ul>"}]},"9":{"id":"924785-s-9","title":"Administration","mono":"<b>Oral<\/b><br\/><ul><li>may be administered with or without food<\/li><li>candesartan oral suspension can be prepared within the range of 0.1 to 2 mg\/mL (typically 1 mg\/mL); use Ora-Plus(R) and Ora-Sweet SF(R) or Ora-Blend SF(R) as vehicle, and dispense the suspension in an amber polyethylene terephthalate (PET) bottle with an expiration date of 100 days when stored at room temperature<\/li><\/ul>"},"10":{"id":"924785-s-10","title":"Monitoring","mono":"<ul><li>heart failure: decreased signs and symptoms of heart failure<\/li><li>hypertension: blood pressure<\/li><li>heart failure patients: renal function, serum potassium; periodically<\/li><\/ul>"},"11":{"id":"924785-s-11","title":"How Supplied","mono":"<ul><li><b>Generic<\/b><br\/>Oral Tablet: 4 MG, 8 MG, 16 MG, 32 MG<br\/><\/li><li><b>Atacand<\/b><br\/>Oral Tablet: 4 MG, 8 MG, 16 MG, 32 MG<br\/><\/li><\/ul>"},"13":{"id":"924785-s-13","title":"Clinical Teaching","mono":"<ul><li>Patient should avoid activities requiring mental alertness or coordination until drug effects are realized.<\/li><li>This drug may cause dizziness or headache.<\/li><li>Instruct patients with a history of heart failure to report signs\/symptoms of hypotension.<\/li><\/ul>"}}}